A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. (English) Zbl 1447.92105
Summary: With the aim of inhibiting cancer growth and reducing the risk of metastasis, pharmaceutical companies in the early 1990s developed anti-metastatic agents called inhibitors of metalloproteinases (MMPi). Despite the promising results obtained in pre-clinical studies, results of phase III trials have been somewhat disappointing for late stage cancer patients. With the aim of mathematically investigating this therapeutic failure, we developed a mechanistically based model which integrates cell cycle regulation and macroscopic tumor dynamics. By simulating the model, we evaluated the efficacy of MMPi therapy. Simulation results predict the lack of efficacy of MMPi in advanced cancer patients. The theoretical model may aid in evaluating the efficacy of anti-metastatic therapies, thus benefiting the design of prospective clinical trials.
Keywords:
multiscale modeling; metalloproteinase inhibitors; cytostatic agents; therapeutic developmentReferences:
| [1] | Ambrosi, D.; Preziosi, L., On the closure of mass balance models for tumor growth, Math. Models Method A Appl. Sci., 12, 737-754 (2002) · Zbl 1016.92016 |
| [2] | Arakelyan, L.; Merbl, Y.; Agur, Z., A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth, Eur. J. Cancer, 41, 159-167 (2005) |
| [3] | Bassukas, I. D., Comparative Gompertzian analysis of alterations of tumor growth patterns, Cancer Res., 54, 4385-4392 (1994) |
| [4] | Blagosklonny, M. V.; Pardee, A. B., The restriction point of the cell cycle, Cell Cycle, 1, 103-110 (2000) |
| [5] | Brunton, G. F.; Wheldon, T. E., The Gompertz equation and the construction of tumor growth curves, Cell Tissue Kinet., 13, 455-460 (1980) |
| [6] | Coussens, L. M.; Fingleton, B.; Matrisian, L. M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387-2392 (2002) |
| [7] | Folkman, J.; Moscona, A., Role of cell shape in growth control, Nature, 273, 345-349 (1978) |
| [8] | Galle, J.; Loeffler, M.; Drasdo, D., Modeling the effect of deregulated proliferation and apoptosis on the growth dynamics of epithelial cell populations in vitro, Biophys. J., 88, 62-75 (2005) |
| [9] | Giavazzi, R.; Taraboletti, G., Preclinical development of metalloproteases inhibitors in cancer therapy, Crit. Rev. Oncol. Hematol., 37, 53-60 (2001) |
| [10] | Greenspan, H. P., Models for the growth of a solid tumor by diffusion, Stud. Appl. Math. LI, 4, 317-340 (1972) · Zbl 0257.92001 |
| [11] | Greenspan, H. P., On the growth and stability of cell cultures and solid tumors, J. Theor. Biol., 1976, 56, 229-242 (1976) |
| [12] | Hahn, W. C.; Weinberg, R. A., Modelling the molecular circuitry of cancer, Nat. Rev. Cancer, 2, 331-341 (2002) |
| [13] | Hanahan, D.; Weinberg, R. A., The hallmarks of cancer, Cell, 100, 57-70 (2000) |
| [14] | Hart, D.; Shochat, E.; Agur, Z., The growth law of primary breast cancer as inferred from mammography screening trials data, Br. J. Cancer, 78, 382-387 (1998) |
| [15] | Hoekstra, R.; Eskens, F. A.; Verweij, J., Matrix metalloproteinase inhibitors: current developments and future perspectives, Oncologist, 6, 415-427 (2001) |
| [16] | Kufe, D. W.; Pollock, R. E.; Weichselbaum, R. R.; Bast, R. C.; Gansler, T. S.; Holland, J. F., Cancer Medicine (2003), BC Decker Inc.: BC Decker Inc. Hamilton, Canada |
| [17] | Pavlaki, M.; Zucker, S., Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials, Cancer Metastasis Rev., 22, 117-203 (2003) |
| [18] | Potten, C. S.; Kellett, M.; Roberts, S. A.; Rew, D. A.; Wilson, G. D., Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine, Gut, 33, 71-78 (1992) |
| [19] | Rew, D. A.; Wilson, G. D.; Taylor, I.; Weaver, P. C., Proliferation characteristics of human colorectal carcinomas measured in vivo, Br. J. Surg., 78, 60-66 (1991) |
| [20] | Ribba, B.; Marron, K.; Agur, Z.; Alarcon, T.; Maini, P. K., A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: investigation of the current protocol through theoretical modelling results, Bull. Math. Biol., 67, 79-99 (2005) · Zbl 1334.92207 |
| [21] | Ribba, B.; Colin, T.; Schnell, S., A multiscale model of cancer, and its use in analyzing irradiation therapies, Theor. Biol. Med. Model., 3, 7 (2006) |
| [22] | Sachs, R. K.; Hlatky, L. R.; Hahnfeldt, P., Simple ODE models of tumor growth and anti-angiogenic or radiation treatment, Math. Comput. Model., 33, 1297-1305 (2001) · Zbl 1004.92023 |
| [23] | Skehan, P.; Friedman, S. J., Deceleratory growth by a rat glial tumor line in culture, Cancer Res., 42, 1636-1640 (1982) |
| [24] | Zucker, S.; Cao, J.; Chen, W. T., Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment, Oncogene, 19, 6642-6650 (2000) |
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.
